Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 6/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.44 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15638719 | 0.96 | CHRNA7 (0.47) | CHRNA7PTGER4HTR7ADRA1DHTR2C | |
| SCHEMBL15638267 | 0.84 | CHRNA7 (0.51) | CHRNA7LMNANPSR1NPC1MAPT | |
| SCHEMBL15636310 | 0.81 | CHRNA7 (0.50) | CHRNA7LMNANPC1MAPTRAB9A | |
| SCHEMBL15635768 | 0.79 | CHRNA7 (0.42) | CHRNA7PTGER4HTR7ADRA1DHTR2C | |
| SCHEMBL870110 | 0.79 | P4HTM (0.55) | PTGER4PPARAMAPT | |
| SCHEMBL870804 | 0.76 | KDM4E (0.55) | SMN1; SMN2LMNANPSR1KDM4CMAPT | |
| SCHEMBL15635601 | 0.76 | CHRNA7 (0.41) | CHRNA7PTGER4SMN1; SMN2LMNANPC1 | |
| SCHEMBL17363137 | 0.76 | CHRNA7 (0.38) | CHRNA7KDM4CMAPTL3MBTL1 | |
| SCHEMBL5317568 | 0.75 | PPARA (0.60) | HTR7ADRA1DHTR2CADRA1AADRA1B | |
| SCHEMBL3576168 | 0.75 | JAK2 (0.43) | CHRNA7PTGER4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903965-B1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | ORION CORP (FI) | 2017-03-01 | — | — | EP | disclosed |
| US-9533952-B2 | N-prop-2-ynyl carboxamide derivatives and their use as TRPA1 antagonists | ORION CORPORATION (FI) | 2017-01-03 | — | — | US | disclosed |
| US-20150376130-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | Orlon Corporation (FI) | 2015-12-31 | — | — | US | disclosed |
| EP-2903965-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | Orion Corporation (FI) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014053694-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | ORION CORPORATION (FI) | 2014-04-10 | — | — | WO | disclosed |
| US-20100076087-A1 | METHODS OF REDUCTION OF INTERPATIENT VARIABILITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076087-A1 | METHODS OF REDUCTION OF INTERPATIENT VARIABILITY | TPMT, GUSB, CYP2D6 | CHRNA7 3272/4885PTGER4 1621/4885HTR7 1539/4885 |
| US-20150376130-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | CHRNA7 255/4885PTGER4 740/4885HTR7 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.